

BRIAN SANDOVAL
Governor



RICHARD WHITLEY, MS
Director

MARTA JENSEN
Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

**2nd REVISED NOTICE OF PUBLIC MEETING – PHARMACY AND THERAPEUTICS
COMMITTEE**

AGENDA

Date of Publication: September 7, 2017

Date and Time of Meeting: Thursday, September 28, 2017 at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

Place of Meeting: **Springs Preserve**
333 S. Valley View Blvd
Las Vegas, Nevada 89107

Place of Meeting: **Division of Public & Behavioral Health**
4150 Technology Way, Room 301
Carson City, Nevada 89706

Please check with staff to verify room location

Webinar Registration: <https://optum.webex.com/optum/onstage/g.php?MTID=e698cdc3c4cbcc31d4c379331a1f8cebe>

OR

www.webex.com, select "Join," enter Meeting Number 644 525 531, your name and email and then select, "Join."

A Password should not be necessary, but if asked, enter "9MMZuC88."

OR

*Nevada Department of Health and Human Services
Helping People -- It's Who We Are And What We Do*

Audio Only: (763) 957-6300

Event Number: 644 525 531

Follow the instructions that appear on your screen to join the teleconference. Audio will also be broadcast over the internet (VoIP).

- 1. Call to Order and Roll Call**
- 2. Public Comment**
- 3. Administrative**
 - a. **For Possible Action:** Review and Approve Meeting Minutes from March 23, 2017
 - b. Status Update by the DHCFP
 1. Public Comment
- 4. Annual Review - Established Drug Classes Being Reviewed Due to the Release of New Drugs**
 - a. Analgesics – Opiate Agonists
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
 - b. Anti-infective Agents – Antivirals – Influenza Agents
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- c. Anti-infective Agents – Quinolones – Quinolones – 3rd Generation
 - 1. Public Comment
 - 2. Drug Class Review Presentation – OptumRx
 - 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- d. Autonomic Agents – Sympathomimetics – Self-Injectable Epinephrine
 - 1. Public Comment
 - 2. Drug Class Review Presentation – OptumRx
 - 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- e. Biologic Response Modifiers – Immunomodulators – Targeted Immunomodulators
 - 1. Public Comment
 - 2. Drug Class Review Presentation – OptumRx
 - 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- f. Biologic Response Modifiers – Multiple Sclerosis Agents – Injectable
 - 1. Public Comment
 - 2. Drug Class Review Presentation – OptumRx
 - 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups

4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- g. Cardiovascular Agents – Antilipemics – Cholesterol Absorption Inhibitors
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- h. Cardiovascular Agents – Antilipemics – HMG-CoA Reductase Inhibitors (Statins)
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- i. Dermatological Agents – Antipsoriatic Agents – Topical Vitamin D Analogs
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- j. Dermatological Agents – Topical Anti-infectives – Topical Antivirals
1. Public Comment

2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- k. Dermatological Agents – Topical Anti-infectives – Topical Scabicides
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- l. Gastrointestinal Agents – Antiulcer Agents – Proton Pump Inhibitors (PPIs)
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- m. Gastrointestinal Agents – Gastrointestinal Anti-inflammatory Agents
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- n. Hematological Agents – Anticoagulants – Injectable
 - 1. Public Comment
 - 2. Drug Class Review Presentation – OptumRx
 - 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- o. Hormones and Hormone Modifiers – Antidiabetic Agents – Biguanides
 - 1. Public Comment
 - 2. Drug Class Review Presentation – OptumRx
 - 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- p. Hormones and Hormone Modifiers – Antidiabetic Agents – Incretin Mimetics
 - 1. Public Comment
 - 2. Drug Class Review Presentation – OptumRx
 - 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- q. Hormones and Hormone Modifiers – Antidiabetic Agents – Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
 - 1. Public Comment
 - 2. Drug Class Review Presentation – OptumRx
 - 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups

4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- r. Musculoskeletal Agents – Bone Resorption Inhibitors – Bisphosphonates
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- s. Neurological Agents – Anti-Migraine Agents – Serotonin-Receptor Agonists
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- t. Ophthalmic Agents – Ophthalmic Anti-infectives – Ophthalmic Quinolones
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- u. Psychotropic Agents – ADHD Agents
1. Public Comment

2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- v. Psychotropic Agents – Antipsychotics – Atypical Antipsychotics – Oral
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- w. Respiratory Agents – Respiratory Anti-inflammatory Agents – Leukotriene Receptor Antagonists
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- x. Respiratory Agents – Respiratory Corticosteroid/Long-Acting Beta-Agonist Combinations
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP

5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

5. Annual Review – Established Drug Classes

a. Cardiovascular Agents – Antihypertensive Agents – Angiotensin II Receptor Antagonists

1. Public Comment
2. Drug Class Review Presentation – OptumRx
3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

b. Cardiovascular Agents – Antihypertensive Agents – Calcium-Channel Blockers

1. Public Comment
2. Drug Class Review Presentation – OptumRx
3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

c. Cardiovascular Agents – Antihypertensive Agents – Vasodilators – Oral

1. Public Comment
2. Drug Class Review Presentation – OptumRx
3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

d. Gastrointestinal Agents – Antiemetics – Miscellaneous

1. Public Comment

2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- e. Hematological Agents – Anticoagulants – Oral
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- f. Hematological Agents – Platelet Inhibitors Public Comment
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- g. Hormones and Hormone Modifiers – Pituitary Hormones – Growth hormone modifiers
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP

5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- h. Neurological Agents – Anticonvulsants
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- i. Ophthalmic Agents – Ophthalmic Anti-infective/Anti-inflammatory Combinations
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- j. Psychotropic Agents – Anxiolytics, Sedatives and Hypnotics
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- k. Respiratory Agents – Nasal Antihistamines
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action

- a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
1. Respiratory Agents – Respiratory Anti-inflammatory Agents – Nasal Corticosteroids
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
6. **Annual Review – Drug Classes Without Proposed Changes**
 - a. Public Comment
 - b. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the division of Health Care Financing and Policy Without Changes
 1. Analgesics - Analgesic/Miscellaneous - Neuropathic Pain/Fibromyalgia Agents
 2. Analgesics - Analgesic/Miscellaneous - Tramadol and Related Drugs
 3. Analgesics - Opiate Agonists - Abuse Deterrent
 4. Analgesics - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral
 5. Antihistamines - H1 blockers - Non-Sedating H1 Blockers
 6. Anti-infective Agents - Antivirals - Alpha Interferons
 7. Anti-infective Agents - Antivirals - Anti-hepatitis Agents - Polymerase Inhibitors/Combination Products
 8. Anti-infective Agents - Antivirals - Anti-hepatitis Agents - Ribavirins
 9. Anti-infective Agents - Antivirals - Anti-Herpetic Agents
 10. Anti-infective Agents - Cephalosporins - Second-Generation Cephalosporins
 11. Anti-infective Agents - Cephalosporins - Third-Generation Cephalosporins
 12. Anti-infective Agents - Macrolides
 13. Anti-infective Agents - Quinolones - Quinolones - 2nd Generation
 14. Biologic Response Modifiers - Multiple Sclerosis Agents - Oral
 15. Biologic Response Modifiers - Multiple Sclerosis Agents - Specific Symptomatic Treatment
 16. Cardiovascular Agents - Antihypertensive Agents - Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
 17. Cardiovascular Agents - Antihypertensive Agents - Beta-Blockers
 18. Cardiovascular Agents - Antihypertensive Agents - Direct Renin Inhibitors

19. Cardiovascular Agents - Antihypertensive Agents - Vasodilators - Inhaled
20. Cardiovascular Agents - Antilipemics - Bile Acid Sequestrants
21. Cardiovascular Agents - Antilipemics - Fibrin Acid Derivatives
22. Cardiovascular Agents - Antilipemics - Niacin Agents
23. Cardiovascular Agents - Antilipemics - Omega-3 Fatty Acids
24. Dermatological Agents - Topical Analgesics
25. Dermatological Agents - Topical Anti-infectives - Acne Agents: Topical, Benzoyl Peroxide, Antibiotics and Combination Products
26. Dermatological Agents - Topical Anti-infectives - Impetigo Agents: Topical
27. Dermatological Agents - Topical Anti-infectives - Topical Antifungals (onychomycosis)
28. Dermatological Agents - Topical Anti-inflammatory Agents - Immunomodulators: Topical
29. Dermatological Agents - Topical Antineoplastics - Topical Retinoids
30. Electrolytic and Renal Agents - Phosphate Binding Agents
31. Gastrointestinal Agents - Antiemetics - Serotonin-receptor antagonists/Combo
32. Gastrointestinal Agents - Antiulcer Agents - H2 blockers
33. Gastrointestinal Agents - Functional Gastrointestinal Disorder Drugs (New)
34. Gastrointestinal Agents - Gastrointestinal Enzymes
35. Genitourinary Agents - Benign Prostatic Hyperplasia (BPH) Agents - 5-Alpha Reductase Inhibitors
36. Genitourinary Agents - Benign Prostatic Hyperplasia (BPH) Agents - Alpha-Blockers
37. Genitourinary Agents - Bladder Antispasmodics
38. Hematological Agents - Erythropoiesis-Stimulating Agents
39. Hormones and Hormone Modifiers - Androgens
40. Hormones and Hormone Modifiers - Antidiabetic Agents - Alpha-Glucosidase Inhibitors/Amylin analogs/Misc.
41. Hormones and Hormone Modifiers - Antidiabetic Agents - Dipeptidyl Peptidase-4 Inhibitors
42. Hormones and Hormone Modifiers - Antidiabetic Agents - Insulins (Vials, Pens and Inhaled)
43. Hormones and Hormone Modifiers - Antidiabetic Agents - Meglitinides
44. Hormones and Hormone Modifiers - Antidiabetic Agents - Sulfonylureas
45. Hormones and Hormone Modifiers - Antidiabetic Agents - Thiazolidinediones
46. Hormones and Hormone Modifiers - Progestins for Cachexia
47. Musculoskeletal Agents - Anticancer Agents
48. Musculoskeletal Agents - Bone Resorption Inhibitors - Nasal Calcitonins
49. Musculoskeletal Agents - Restless Leg Syndrome Agents
50. Musculoskeletal Agents - Skeletal Muscle Relaxants
51. Neurological Agents - Alzheimer's Agents
52. Neurological Agents - Anticonvulsants - Barbiturates
53. Neurological Agents - Anticonvulsants - Benzodiazepines
54. Neurological Agents - Anticonvulsants - Hydantoins
55. Neurological Agents - Antiparkinsonian Agents - Non-ergot Dopamine Agonists
56. Ophthalmic Agents - Antiglaucoma Agents - Carbonic Anhydrase Inhibitors/Beta-Blockers

57. Ophthalmic Agents - Antiglaucoma Agents - Ophthalmic Prostaglandins
58. Ophthalmic Agents - Ophthalmic Antihistamines
59. Ophthalmic Agents - Ophthalmic Anti-infectives - Ophthalmic Macrolides
60. Ophthalmic Agents - Ophthalmic Anti-inflammatory Agents - Ophthalmic Corticosteroids
61. Ophthalmic Agents - Ophthalmic Anti-inflammatory Agents - Ophthalmic Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
62. Ophthalmic Agents - Ophthalmics for Dry Eye Disease
63. Otic Agents - Otic Anti-infectives - Otic Quinolones
64. Psychotropic Agents - Antidepressants - Other
65. Psychotropic Agents - Antidepressants - Selective Serotonin Reuptake Inhibitors (SSRIs)
66. Psychotropic Agents - Psychostimulants - Narcolepsy Agents
67. Respiratory Agents - Respiratory Anti-inflammatory Agents - Respiratory Corticosteroids
68. Respiratory Agents - Respiratory Anti-inflammatory Agents - Phosphodiesterase Type 4 Inhibitors
69. Respiratory Agents - Respiratory Antimuscarinics
70. Respiratory Agents - Respiratory Beta-Agonists - Long-Acting Respiratory Beta-Agonist
71. Respiratory Agents - Respiratory Beta-Agonists - Short-Acting Respiratory Beta-Agonist
72. Respiratory Agents - Respiratory Long-Acting Antimuscarinic/Long-Acting Beta-Agonist Combinations
73. Toxicology Agents - Antidotes - Opiate Antagonists
74. Toxicology Agents - Substance Abuse Agents - Mixed Opiate Agonists/Antagonists

- c. **For Possible Action:** Committee Discussion and Approval of the Drug Classes without Changes

7. Report by OptumRx on New Drugs to Market, New Generic Drugs to Market and New Line Extensions

8. Closing Discussion

- a. Public comments on any subject
- b. Date and location of the next meeting
- c. Adjournment

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to five minutes.

This notice and agenda have been posted at <http://dhcfp.nv.gov/> and notice.nv.gov/.

Notice of this meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site <http://dhcfp.nv.gov/> Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a draft copy of the changes will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the Colleen McLachlan at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at: cmclach@dhcfp.nv.gov, in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Colleen McLachlan at (775) 684-3722.
